Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer By Reuters June 16, 20252:24 PM PDTUpdated June 16, 2025 ...

Regeneron is down 31.4% since the beginning of the year, and at $490.50 per share, it is trading 59.2% below its 52-week high of $1,202 from August 2024. Investors who bought $1,000 worth of ...

Anne Wojcicki, the co-founder and former CEO of 23andMe MEHCQ -0.32%, is poised to regain control of the DNA-testing company after a nonprofit she controls topped a prior bid. 23andMe said Friday ...

Biotechnology company Regeneron buying 23andMe for $256 million By: Michelle Chapman, The Associated Press Posted: 8:00 AM CDT Monday, May. 19, 2025 Last Modified: 8:44 AM CDT Monday, May. 19, 2025 ...

(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied ...